KRAS and breast carcinoma: Figure 7A showed the expression level of ALG3 in breast cancer samples. The subclusters was identified as ALG3+ and ALG3-, as shown in Figure 7B. The analysis revealed that ALG3 was positively associated with the GSVA scores of pathways that were involved in breast cancer progression, such as KRAS signaling, EMT, TNF α signaling pathways. Interestingly, ALG3 was positively associated with the GSVA scores of bile acid and glycolysis metabolism (Figure 7C).